Profile data is unavailable for this security.
About the company
Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.
- Revenue in USD (TTM)11.53bn
- Net income in USD733.00m
- Incorporated1931
- Employees50.00k
- LocationBaxter International Inc1 Baxter PkwyDEERFIELD 60015-4625United StatesUSA
- Phone+1 (847) 948-2000
- Fax+1 (302) 655-5049
- Websitehttps://www.baxter.com/
Mergers & acquisitions
| Acquired company | BAX:NYQ since announced | Transaction value |
|---|---|---|
| Omnicell Inc | 2.92% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| West Pharmaceutical Services Inc. | 2.04bn | 311.70m | 22.07bn | 8.20k | 72.42 | 12.83 | 54.91 | 10.83 | 4.12 | 4.12 | 26.94 | 23.26 | 0.8566 | 5.05 | 5.91 | 248,451.20 | 12.40 | 9.48 | 14.85 | 11.20 | 34.85 | 32.49 | 14.48 | 10.89 | 2.11 | -- | 0.1295 | 21.64 | 7.13 | 5.30 | 18.25 | 13.72 | 2.43 | 8.27 |
| ResMed Inc. | 3.03bn | 679.90m | 31.43bn | 7.77k | 46.54 | 11.73 | 37.58 | 10.38 | 4.66 | 4.66 | 20.76 | 18.49 | 0.6901 | 3.03 | 6.20 | 389,691.10 | 15.50 | 12.62 | 17.81 | 14.75 | 58.29 | 57.71 | 22.45 | 18.46 | 1.80 | 15.53 | 0.2828 | 45.44 | 13.44 | 11.99 | 51.41 | 11.99 | 8.05 | 6.85 |
| Zimmer Biomet Holdings Inc | 7.06bn | -151.90m | 33.13bn | 19.90k | -- | 2.79 | 38.02 | 4.69 | -0.7559 | -0.7559 | 34.06 | 57.27 | 0.2923 | 0.87 | 5.67 | 355,020.10 | -0.6198 | 1.45 | -0.7084 | 1.60 | 70.11 | 70.72 | -2.12 | 4.69 | 1.17 | 9.17 | 0.411 | 53.74 | 0.6215 | 11.30 | 405.10 | 9.46 | 16.05 | 1.76 |
| DexCom, Inc. | 1.82bn | 231.10m | 34.59bn | 3.90k | 149.11 | 23.06 | 118.41 | 19.00 | 2.42 | 2.42 | 19.00 | 15.62 | 0.605 | 3.82 | 6.02 | 466,820.50 | 7.68 | -1.96 | 8.91 | -2.31 | 66.32 | 65.65 | 12.69 | -2.24 | 6.00 | 5.92 | 0.5313 | -- | 43.08 | 41.61 | 179.29 | -- | 61.86 | -- |
| Baxter International Inc | 11.53bn | 733.00m | 41.15bn | 50.00k | 57.16 | 4.80 | 26.36 | 3.57 | 1.41 | 1.76 | 22.42 | 16.77 | 0.6167 | 3.67 | 6.05 | 230,620.00 | 3.97 | 9.52 | 4.74 | 11.99 | 41.12 | 42.29 | 6.43 | 16.39 | 2.06 | 13.44 | 0.4299 | 24.49 | 2.37 | 1.17 | -40.00 | 12.04 | -18.18 | -16.14 |
| Align Technology, Inc. | 2.29bn | 1.74bn | 43.59bn | 14.53k | 25.15 | 14.37 | 23.84 | 19.06 | 21.99 | 21.99 | 28.94 | 38.47 | 0.6761 | 6.08 | 3.95 | 157,412.80 | 51.38 | 18.60 | 72.82 | 26.41 | 71.04 | 74.16 | 75.99 | 19.47 | 1.20 | -- | 0.00 | 0.00 | 22.39 | 25.87 | 10.63 | 24.87 | 44.10 | -- |
| Boston Scientific Corporation | 10.11bn | -417.00m | 50.59bn | 36.00k | -- | 3.25 | 71.56 | 5.00 | -0.2938 | 2.61 | 7.13 | 10.87 | 0.351 | 2.22 | 5.96 | 280,805.60 | -1.39 | 3.27 | -1.59 | 4.13 | 66.70 | 70.79 | -3.95 | 7.20 | 1.42 | 3.33 | 0.3749 | 0.00 | 9.28 | 7.78 | -62.72 | -- | 16.44 | -- |
| Edwards Lifesciences Corp | 4.37bn | 796.90m | 54.75bn | 13.90k | 70.18 | 13.00 | 61.15 | 12.53 | 1.25 | 1.25 | 6.92 | 6.76 | 0.6844 | 1.55 | 7.80 | 314,295.00 | 12.48 | 15.19 | 14.30 | 18.11 | 75.50 | 74.39 | 18.24 | 21.99 | 2.61 | -- | 0.1238 | 0.00 | 16.79 | 13.36 | 42.24 | 5.29 | 24.33 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2020 | 37.08m | 7.26% |
| Wellington Management Co. LLPas of 30 Sep 2020 | 28.75m | 5.63% |
| BlackRock Fund Advisorsas of 30 Sep 2020 | 28.67m | 5.61% |
| SSgA Funds Management, Inc.as of 30 Sep 2020 | 22.22m | 4.35% |
| Morgan Stanley Investment Management Ltd.as of 30 Sep 2020 | 21.96m | 4.30% |
| Capital Research & Management Co. (International Investors)as of 30 Sep 2020 | 11.96m | 2.34% |
| Generation Investment Management LLPas of 30 Sep 2020 | 11.86m | 2.32% |
| Veritas Asset Management LLPas of 30 Sep 2020 | 10.95m | 2.14% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2020 | 8.17m | 1.60% |
| The Caisse de d�p�t et placement du Qu�becas of 30 Sep 2020 | 7.87m | 1.54% |
